piperidines and Leukemia--Prolymphocytic--B-Cell

piperidines has been researched along with Leukemia--Prolymphocytic--B-Cell* in 6 studies

Reviews

1 review(s) available for piperidines and Leukemia--Prolymphocytic--B-Cell

ArticleYear
Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review.
    Haematologica, 2022, 05-01, Volume: 107, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Leukemia, Prolymphocytic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Tumor Suppressor Protein p53

2022

Other Studies

5 other study(ies) available for piperidines and Leukemia--Prolymphocytic--B-Cell

ArticleYear
Initial treatment of B-cell prolymphocytic leukemia with ibrutinib.
    American journal of hematology, 2020, Volume: 95, Issue:5

    Topics: Adenine; Aged; Female; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Survival Analysis

2020
Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia.
    Investigational new drugs, 2020, Volume: 38, Issue:5

    B cell prolymphocytic leukemia (B-PLL) is a rare and aggressive disease that is associated with poor survival. Although initially asymptomatic patients do not require therapy, most patients will progress and inevitably require treatment. More than 50% of patients with B-PLL carry abnormalities in the TP53 tumor suppressor gene and/or complex karyotype and show resistance to conventional chemotherapy. The efficacy of ibrutinib, a B cell receptor inhibitor, for B-PLL with the TP53 abnormality as second-line therapy was recently demonstrated. We herein report that low-dose ibrutinib as upfront therapy induced a complete response in a B-PLL patient with the TP53 abnormality, whose condition has since remained stable with no recurrence for 12 months. Effective treatments for B-PLL are lacking and given its rarity, prospective comparative therapies are not yet available. This case suggests that upfront therapy with ibrutinib improves the outcome of B-PLL.

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Mutation; Piperidines; Protein Kinase Inhibitors; Treatment Outcome; Tumor Suppressor Protein p53

2020
B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib.
    Pathology, 2020, Volume: 52, Issue:4

    Topics: Adenine; Aged; Antineoplastic Agents; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Receptor, Fibroblast Growth Factor, Type 3

2020
Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors.
    British journal of haematology, 2019, Volume: 186, Issue:4

    Topics: Adenine; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Substitution; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Retreatment; Rituximab; Signal Transduction; Sulfonamides; Treatment Outcome

2019
Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:3

    Topics: Adenine; Aged; Gene Rearrangement; Humans; Leukemia, Prolymphocytic, B-Cell; Male; Piperidines; Prognosis; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyrimidines

2018